137 related articles for article (PubMed ID: 20967514)
1. Short-term outcomes of cetuximab combined with standard chemotherapy as first line setting for Chinese patients with non-small cell lung cancer: a report of 12 cases.
Xia LP; Qiu HJ; Chen XX; Hu PL; Guo GF; Wang F; Zhou FF; He WZ; Zhang B; Zhang L
Med Oncol; 2011 Dec; 28 Suppl 1():S570-6. PubMed ID: 20967514
[TBL] [Abstract][Full Text] [Related]
2. [Short-term outcomes of 16 patients with non-small cell lung cancer receiving cetuximab combined with standard chemotherapy in the first and non-first line settings].
Qiu HJ; Xia LP; Wang F; Guo GF; Zhou FF; Zhang B; Zhang L
Nan Fang Yi Ke Da Xue Xue Bao; 2010 Nov; 30(11):2423-6. PubMed ID: 21097395
[TBL] [Abstract][Full Text] [Related]
3. First-cycle rash and survival in patients with advanced non-small-cell lung cancer receiving cetuximab in combination with first-line chemotherapy: a subgroup analysis of data from the FLEX phase 3 study.
Gatzemeier U; von Pawel J; Vynnychenko I; Zatloukal P; de Marinis F; Eberhardt WE; Paz-Ares L; Schumacher KM; Goddemeier T; O'Byrne KJ; Pirker R
Lancet Oncol; 2011 Jan; 12(1):30-7. PubMed ID: 21169060
[TBL] [Abstract][Full Text] [Related]
4. [Efficacy of cetuximab combined with chemotherapy for patients with advanced colorectal cancer and unclear K-ras status].
Guo GF; Xia LP; Qiu HJ; Xu RH; Zhang B; Jiang WQ; Zhou FF; Wang F
Zhonghua Zhong Liu Za Zhi; 2010 Oct; 32(10):777-81. PubMed ID: 21163071
[TBL] [Abstract][Full Text] [Related]
5. [Efficacy of cetuximab combined with chemotherapy on advanced colorectal cancer: a report of 53 cases].
Guo GF; Xia LP; Zhang B; Jiang WQ; Liu MZ; Hu PL; Chen XX; Qiu HJ; Zhou FF
Ai Zheng; 2009 Dec; 28(12):1317-23. PubMed ID: 19958628
[TBL] [Abstract][Full Text] [Related]
6. [Short-term efficacy of cetuximab combined with radiotherapy or chemotherapy on head and neck cancer: a report of 11 cases].
Xia LP; Zhang B; Liu MZ; Hu PL; Chen XX; Guo GF; Qiu HJ; Rong YM; Qian SY; Zhou FF; Huang YY; Wang TL
Ai Zheng; 2009 Sep; 28(9):977-82. PubMed ID: 19728918
[TBL] [Abstract][Full Text] [Related]
7. Phase II study of cetuximab, docetaxel, and gemcitabine in patients with previously untreated advanced non-small-cell lung cancer.
Spigel DR; Greco FA; Thompson DS; Webb C; Rubinsak J; Inhorn RC; Reeves J; Vazquez ER; Lane CM; Burris HA; Hainsworth JD
Clin Lung Cancer; 2010 May; 11(3):198-203. PubMed ID: 20439197
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of a novel rash scale and a serum proteomic predictor in a randomized phase II trial of sequential or concurrent cetuximab and pemetrexed in previously treated non-small cell lung cancer.
Maitland ML; Levine MR; Lacouture ME; Wroblewski KE; Chung CH; Gordon IO; Szeto L; Ratko G; Soltani K; Kozloff MF; Hoffman PC; Salgia R; Carbone DP; Karrison TG; Vokes EE
BMC Cancer; 2014 Jan; 14():5. PubMed ID: 24386952
[TBL] [Abstract][Full Text] [Related]
9. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial.
Pirker R; Pereira JR; Szczesna A; von Pawel J; Krzakowski M; Ramlau R; Vynnychenko I; Park K; Yu CT; Ganul V; Roh JK; Bajetta E; O'Byrne K; de Marinis F; Eberhardt W; Goddemeier T; Emig M; Gatzemeier U;
Lancet; 2009 May; 373(9674):1525-31. PubMed ID: 19410716
[TBL] [Abstract][Full Text] [Related]
10. Cetuximab and first-line taxane/carboplatin chemotherapy in advanced non-small-cell lung cancer: results of the randomized multicenter phase III trial BMS099.
Lynch TJ; Patel T; Dreisbach L; McCleod M; Heim WJ; Hermann RC; Paschold E; Iannotti NO; Dakhil S; Gorton S; Pautret V; Weber MR; Woytowitz D
J Clin Oncol; 2010 Feb; 28(6):911-7. PubMed ID: 20100966
[TBL] [Abstract][Full Text] [Related]
11. Increased EGFR gene copy number detected by fluorescent in situ hybridization predicts outcome in non-small-cell lung cancer patients treated with cetuximab and chemotherapy.
Hirsch FR; Herbst RS; Olsen C; Chansky K; Crowley J; Kelly K; Franklin WA; Bunn PA; Varella-Garcia M; Gandara DR
J Clin Oncol; 2008 Jul; 26(20):3351-7. PubMed ID: 18612151
[TBL] [Abstract][Full Text] [Related]
12. Multicenter phase I/II study of cetuximab with paclitaxel and carboplatin in untreated patients with stage IV non-small-cell lung cancer.
Thienelt CD; Bunn PA; Hanna N; Rosenberg A; Needle MN; Long ME; Gustafson DL; Kelly K
J Clin Oncol; 2005 Dec; 23(34):8786-93. PubMed ID: 16246975
[TBL] [Abstract][Full Text] [Related]
13. Phase I/IIa study of cetuximab with gemcitabine plus carboplatin in patients with chemotherapy-naive advanced non-small-cell lung cancer.
Robert F; Blumenschein G; Herbst RS; Fossella FV; Tseng J; Saleh MN; Needle M
J Clin Oncol; 2005 Dec; 23(36):9089-96. PubMed ID: 16301597
[TBL] [Abstract][Full Text] [Related]
14. Randomized phase II study of cetuximab plus cisplatin/vinorelbine compared with cisplatin/vinorelbine alone as first-line therapy in EGFR-expressing advanced non-small-cell lung cancer.
Rosell R; Robinet G; Szczesna A; Ramlau R; Constenla M; Mennecier BC; Pfeifer W; O'Byrne KJ; Welte T; Kolb R; Pirker R; Chemaissani A; Perol M; Ranson MR; Ellis PA; Pilz K; Reck M
Ann Oncol; 2008 Feb; 19(2):362-9. PubMed ID: 17947225
[TBL] [Abstract][Full Text] [Related]
15. EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study.
Pirker R; Pereira JR; von Pawel J; Krzakowski M; Ramlau R; Park K; de Marinis F; Eberhardt WE; Paz-Ares L; Störkel S; Schumacher KM; von Heydebreck A; Celik I; O'Byrne KJ
Lancet Oncol; 2012 Jan; 13(1):33-42. PubMed ID: 22056021
[TBL] [Abstract][Full Text] [Related]
16. Phase II study of pemetrexed and cisplatin plus cetuximab followed by pemetrexed and cetuximab maintenance therapy in patients with advanced nonsquamous non-small cell lung cancer.
Schmid-Bindert G; Gebbia V; Mayer F; Arriola E; Márquez-Medina D; Syrigos K; Biesma B; Leschinger MI; Frimodt-Moller B; Ripoche V; Myrand SP; Nguyen TS; Hozak RR; Zimmermann A; Visseren-Grul C; Schuette W
Lung Cancer; 2013 Sep; 81(3):428-434. PubMed ID: 23790468
[TBL] [Abstract][Full Text] [Related]
17. Continued use of afatinib with the addition of cetuximab after progression on afatinib in patients with EGFR mutation-positive non-small-cell lung cancer and acquired resistance to gefitinib or erlotinib.
Horn L; Gettinger S; Camidge DR; Smit EF; Janjigian YY; Miller VA; Pao W; Freiwald M; Fan J; Wang B; Chand VK; Groen HJM
Lung Cancer; 2017 Nov; 113():51-58. PubMed ID: 29110849
[TBL] [Abstract][Full Text] [Related]
18. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
19. Docetaxel-carboplatin chemotherapy combined with cetuximab in patients with locally advanced or metastatic non small-cell lung cancer (NSCLC)--results of the nonrandomised phase II study TaxErb.
Fischer JR; Griesinger F; Fink T; Salm T; Marseille A; Wolf M
Lung Cancer; 2012 Mar; 75(3):348-52. PubMed ID: 21908069
[TBL] [Abstract][Full Text] [Related]
20. Weekly and every 2 weeks cetuximab maintenance therapy after platinum-based chemotherapy plus cetuximab as first-line treatment for non-small cell lung cancer: randomized non-comparative phase IIIb NEXT trial.
Heigener DF; Pereira JR; Felip E; Mazal J; Manzyuk L; Tan EH; Merimsky O; Sarholz B; Esser R; Gatzemeier U
Target Oncol; 2015 Jun; 10(2):255-65. PubMed ID: 25195590
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
